126 related articles for article (PubMed ID: 32744380)
1. Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter-2 inhibitor, in Chinese people with type 2 diabetes mellitus.
Li X; Zhu X; Liu J; Li Q; Zhang H; Li C; Wu M; Gao L; Wen H; Li X; Tang X; Liu L; Ding Y
Diabetes Obes Metab; 2020 Dec; 22(12):2316-2324. PubMed ID: 32744380
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
[TBL] [Abstract][Full Text] [Related]
3. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods.
Song L; Yao X; Liu Y; Zhong W; Jiang J; Liu H; Zhou H; Shi C; Zong K; Wang C; Ma C; Liu D; Hu P
Eur J Pharm Sci; 2020 Apr; 147():105281. PubMed ID: 32126254
[TBL] [Abstract][Full Text] [Related]
4. A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor.
Song L; Wang X; Sun J; Hu X; Li H; Hu P; Liu D
Clin Pharmacokinet; 2023 Mar; 62(3):505-518. PubMed ID: 36802026
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus.
Zhang H; Zhu X; Li X; Chen H; Wu M; Li C; Liu J; Liu C; Zhang Y; Ding Y
Diabetes Obes Metab; 2020 Feb; 22(2):191-202. PubMed ID: 31588657
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment.
Zhao H; Zhao Z; He K; Mi N; Lou K; Dong X; Zhang W; Sun J; Hu X; Pang S; Cheng H; Wen Q
Clin Pharmacokinet; 2023 Aug; 62(8):1093-1103. PubMed ID: 37284974
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
Kasichayanula S; Chang M; Hasegawa M; Liu X; Yamahira N; LaCreta FP; Imai Y; Boulton DW
Diabetes Obes Metab; 2011 Apr; 13(4):357-65. PubMed ID: 21226818
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
Yong X; Wen A; Liu X; Liu H; Liu YP; Li N; Hu T; Chen Y; Wang M; Wang L; Dai X; Huang J; Li J; Shen H
Clin Drug Investig; 2016 Mar; 36(3):195-202. PubMed ID: 26692004
[TBL] [Abstract][Full Text] [Related]
9. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
[TBL] [Abstract][Full Text] [Related]
10. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
[TBL] [Abstract][Full Text] [Related]
11. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
Sasaki T; Seino Y; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Adv Ther; 2015 Apr; 32(4):319-40. PubMed ID: 25855342
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent glucosuria of DWP16001, a novel selective sodium-glucose cotransporter-2 inhibitor, in healthy subjects.
Hwang JG; Lee S; Huh W; Han J; Oh J; Jang IJ; Yu KS
Br J Clin Pharmacol; 2022 Sep; 88(9):4100-4110. PubMed ID: 35395697
[TBL] [Abstract][Full Text] [Related]
14. Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model.
Zhao H; Wei Y; He K; Zhao X; Mu H; Wen Q
Eur J Pharm Sci; 2022 Dec; 179():106298. PubMed ID: 36162752
[TBL] [Abstract][Full Text] [Related]
15. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
Kapur A; O'Connor-Semmes R; Hussey EK; Dobbins RL; Tao W; Hompesch M; Smith GA; Polli JW; James CD; Mikoshiba I; Nunez DJ
BMC Pharmacol Toxicol; 2013 May; 14():26. PubMed ID: 23668634
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
Tirucherai GS; LaCreta F; Ismat FA; Tang W; Boulton DW
Diabetes Obes Metab; 2016 Jul; 18(7):678-84. PubMed ID: 27291448
[TBL] [Abstract][Full Text] [Related]
18. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Veltkamp SA; Kadokura T; Krauwinkel WJ; Smulders RA
Clin Drug Investig; 2011 Dec; 31(12):839-51. PubMed ID: 21877761
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Kasichayanula S; Liu X; Lacreta F; Griffen SC; Boulton DW
Clin Pharmacokinet; 2014 Jan; 53(1):17-27. PubMed ID: 24105299
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
Watada H; Shiramoto M; Ueda S; Tang W; Asano M; Thorén F; Kim H; Yajima T; Boulton DW; Araki E
Diabetes Obes Metab; 2019 Apr; 21(4):876-882. PubMed ID: 30499157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]